A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

Maryland’s Medicaid program now offers partial coverage of popular obesity drugs, with the state spending more than $68 ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Statements by Robert F. Kennedy Jr. and Elon Musk tap into a dispute over whether lifestyle changes or drugs are a better way to treat obesity.

The Biden administration has unveiled a major proposal to expand Medicare and Medicaid coverage for anti-obesity drugs, ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

We have been giving a lot of attention to RFK Jr recently, with good reason. He is poised to be put in charge of the federal ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...

Semaglutide and similar medications could be key players in bending the curve but enduring change ultimately hinges on a ...